Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.
IPO Year:
Exchange: AMEX
Website: isoray.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/14/2021 | $1.25 | Outperform | Northland Capital Markets |
Northland Capital Markets initiated coverage of Isoray with a rating of Outperform and set a new price target of $1.25
Lake Street initiated coverage of IsoRay with a rating of Buy and set a new price target of $3.00
HC Wainwright & Co. reiterated coverage of Isoray with a rating of Buy and set a new price target of $2.10 from $1.25 previously
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE:ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, today announced unaudited financial results for the three months ended December 31, 2022. "The fourth quarter represented a transformational period leading up to the completed merger between Isoray and Viewpoint Molecular Targeting. In the Company's core brachytherapy business lack of orders from our largest customer and post-COVID recovery
RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2023 ended September 30, 2022 and provided updates regarding the pending merger with Viewpoint Molecular Targeting. Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company. "The pending merger represents an exciting transformational opportunity for Isoray and all our stakeholders. It provides us with the opportunity to build on Isoray's existing business with a pipeline of very
RICHLAND, Wash., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2023 ended September 30, 2022 on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the first quarter fiscal year 2023 after the close of the U.S. stock markets on November 10, 2022. To listen to the conference call, please dial (877) 545-0320. For callers outside the U.S., please dial (973) 528-0002
RICHLAND, Wash., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a definitive agreement to acquire Viewpoint Molecular Targeting, Inc. (Viewpoint) a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. Under the terms of the agreement, a newly formed wholly owned subsidiary of Isoray will merge with and into Viewpoint, with Viewpoint becoming a wholly owned subsidiary of Isoray. At the effective time of the merger, each issued and outstanding share of common stock of Viewpoint will be converted into the right to r
RICHLAND, Wash., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the fourth quarter and fiscal year ended June 30, 2022 on Wednesday, September 28, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2022 after the close of the U.S. stock markets on September 28, 2022. To listen to the conference call, please dial 888-506-0062. For callers outside the U.S., please dial 973-528-0011. The conference call will be
Revenue Increased 12% Year-Over-YearRecord Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, Wash., May 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced its financial results for the third quarter of fiscal 2022 ended March 31, 2022. Revenue for the third quarter of fiscal 2022 grew 12% to $2.91 million versus $2.60 million in the prior year comparable period. The Company's core prostate brachytherapy revenue increased 8% versus the third quarter of fiscal 2021. Prostate brachytherapy represented 75% of total revenue for the third quarter of fiscal 2022 compared to 78% in the pr
RICHLAND, Wash., April 29, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the third quarter fiscal 2022 ended March 31, 2022 on Tuesday, May 10, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the third quarter fiscal year 2022 after the close of the U.S. stock markets on Tuesday, May 10, 2022. To listen to the conference call, please dial (888) 506-0062. For callers outside the U.S., please dial (973) 528-0011. The conference call will be simultaneously webcast and c
Revenue Increased 19% Year-Over-YearProstate Brachytherapy Revenue Increased 13% Year-Over-Year RICHLAND, Wash., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced its financial results for the second quarter of fiscal 2022 ended December 31, 2021. Revenue for the second quarter of fiscal 2022 grew 19% to $2.82 million versus $2.36 million in the prior year comparable period. The Company's core prostate brachytherapy revenue increased 13% versus the second quarter of fiscal 2021. Prostate brachytherapy represented 76% of total revenue for the second quarter of fiscal 2022 compared to 80% in the prio
RICHLAND, Wash., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the second quarter fiscal 2022 ended December 31, 2021 on Tuesday, February 8, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the second quarter fiscal year 2022 after the close of the U.S. stock markets on Tuesday, February 8, 2022. To listen to the conference call, please dial (888) 506-0062. For callers outside the U.S., please dial (973) 528-0011. The conference call will be simultaneously webcas
Prostate Revenue Increased Year-Over-Year for Second Consecutive QuarterNon-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2022 ended September 30, 2021. Revenue for the first quarter of fiscal 2022 grew 8% to $2.56 million versus $2.38 million in the prior year comparable period. The company's core prostate brachytherapy revenue increased 4% versus the first quarter of fiscal 2021. Prostate brachytherapy represen
SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)
SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
D - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
424B5 - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
424B5 - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K/A - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
RICHLAND, Wash., April 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed Vice President, Sales and Marketing. CEO Lori Woods said Fort's appointment adds key expertise. "I am very excited to welcome Donna to the Isoray team. Donna brings some twenty-five years of experience in driving increased company revenue and in building and leading sales and marketing teams. Donna also brings a keen understanding of radiation therapy sequencing, and combination therapy with oncologic agents including immunotherapy to her role at Isoray." Woods concluded, "We believe Donna's proven d
RICHLAND, Wash. & CORALVILLE, Iowa, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (formerly known as "Isoray, Inc.") (NYSE:CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, announced the presentation of extremely encouraging results regarding 212Pb-VMT-α-NET, its lead preclinical candidate for neuroendocrine tumors (NET), currently being used therapeutically in India on a compassionate use basis. Dr Vikas Prasad presented the results at the 2023 PET Radiotracer Translation and Resource Center (PET-RTRC) Work
RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE:ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, today announced unaudited financial results for the three months ended December 31, 2022. "The fourth quarter represented a transformational period leading up to the completed merger between Isoray and Viewpoint Molecular Targeting. In the Company's core brachytherapy business lack of orders from our largest customer and post-COVID recovery
Company's focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy and its newly merged partner Viewpoint Molecular Targeting, Inc., today announced that they are now doing business as Perspective Therapeutics, Inc., along with a new brand identity effective immediately. Isoray, Inc. will change its name to Perspective Therapeutics, Inc. by filing an amendment to its
The combination delivers the promise of bringing powerful new perspectives to the rapidly emerging field of Alpha-Particle radiopharmaceuticals Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting, Inc. The combined companies' focus will be the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies so that precision, targeted medical doses are delivered directly to cancer patient tumor sites. Viewpoint Molecular Targeting CEO Thijs Spoor has been named Chief Executive Officer and outgoing Isoray CEO Lori W
RICHLAND, Wash., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced the results of its adjourned Fiscal 2023 Annual Meeting of Stockholders which was held on January 27, 2023. The stockholders approved Proposal One which amends the Company's Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 750,000,000 shares. Proposal One, which required an affirmative vote of a majority of the outstanding common stock for passage, received 71,844,322 share votes in favor of the proposal which represents 50.55% o
RICHLAND, Wash., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the January 12th, 2023, adjourned Annual Meeting of Stockholders is being adjourned until January 27th, 2023, to provide stockholders who have not yet voted with additional time to vote on Proposal 1, approval of an amendment to the Company's Certificate of Incorporation to increase the total number of authorized shares of Common Stock. This vote, which requires approval by a majority of the outstanding shares, is required to proceed with the proposed merger with Viewpoint
RICHLAND, Wash., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the December 13th, 2022, Annual Meeting is being adjourned until January 12th, 2023, to provide stockholders with additional time to vote on Proposal 1, approval of an amendment to the Company's Certificate of Incorporation to increase the total number of authorized shares of Common Stock. This vote, which requires approval by a majority of the outstanding shares, is required to proceed with the proposed merger with Viewpoint Molecular Targeting, Inc. The Board of Director
RICHLAND, Wash., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the December 13th, 2022, Annual Meeting is being adjourned until January 12th, 2023, to provide stockholders with additional time to vote on Proposal 1, approval of an amendment to the Company's Certificate of Incorporation to increase the total number of authorized shares of Common Stock. This vote, which requires approval by a majority of the outstanding shares, is required to proceed with the proposed merger with Viewpoint Molecular Targeting, Inc. The Board of Director
RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2023 ended September 30, 2022 and provided updates regarding the pending merger with Viewpoint Molecular Targeting. Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company. "The pending merger represents an exciting transformational opportunity for Isoray and all our stakeholders. It provides us with the opportunity to build on Isoray's existing business with a pipeline of very
RICHLAND, Wash., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2023 ended September 30, 2022 on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the first quarter fiscal year 2023 after the close of the U.S. stock markets on November 10, 2022. To listen to the conference call, please dial (877) 545-0320. For callers outside the U.S., please dial (973) 528-0002
IsoRay (AMEX:ISR) reported quarterly losses of $(0.02) per share. This is a 100 percent decrease over losses of $(0.01) per share from the same period last year. The company reported $1.83 million in sales this quarter. This is a 34.84 percent decrease over sales of $2.82 million the same period last year.
-SEC Filing
The Dow Jones closed lower by nearly 500 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Isoray The Trade: Isoray, Inc. (NASDAQ:ISR) CFO Jonathan Hunt bought a total of 85,404 shares at an average price of $0.38. To acquire these shares, it cost around $32.5 thousand. What’s H
510(k) Premarket Notification (fda.gov)
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter. • Wix.com (NASDAQ:WIX) is expected to report quarterly loss at $0.09 per share on revenue of $343.33 million. • ArcelorMittal (NYSE:MT) is estimated to report quarterly earnings at $1.25 per share on revenue of $18.36 billion. • Navios Maritime Partners (NYSE:NMM) is estimated to report earnings for its third quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated to report earnings for its third quarter. • Dillard's (NYSE:DDS) is estimated to report earnings for its third quarter. • VerifyMe (NASDAQ:VRME) is projected to report earnings for its third quarter. • Wa
Gainers LogicBio Therapeutics, Inc. (NASDAQ:LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share. FedNat Holding Company (NASDAQ:FNHC) jumped 308.7% to close at $0.47 after dipping around 28% on Friday. Oblong, Inc. (NASDAQ:OBLG) gained 167% to settle at $0.40. Shares of several companies in the technology sector traded higher as stocks rebound following recent weakness. FingerMotion, Inc. (NASDAQ:FNGR) shares rose 92.9% to close at $6.50 after the stock rose more than 80% Friday. Wearable Devices Ltd. (NASDAQ:WLDS) gained 48.9% to close at $1.31 after declining around 8% on Fr
Gainers Senti Biosciences, Inc. (NASDAQ:SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target. BigBear.ai Holdings, Inc. (NYSE:BBAI) climbed 30.3% to close at $1.55 after the company announced it was awarded a $14.8 million U.S. Army Global Force Information Management system contract. Vertical Aerospace Ltd. (NASDAQ:EVTL) gained 27.2% to close at $9.64. Avalon GloboCare Corp. (NASDAQ:AVCO) gained 25.8% to close at $0.7049. Avalon GloboCare received allowance for joint U.S. Patent. TuanChe Limited (NASDAQ:TC) gained 25.3% to close at $3.07. TuanChe posted a H1 loss of $0.11 per share. Ocu
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 500 points on Thursday. The Dow traded down 2.04% to 29,078.45 while the NASDAQ fell 3.59% to 10,655.25. The S&P 500 also fell, dropping, 2.53% to 3,625.09. Also check this: Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday Leading and Lagging Sectors Energy shares fell by just 0.2% on Thursday. In trading on Thursday, consumer discretionary shares dipped by 3.7%. Top Headline The US economy shrank an annualized 0.6% on quarter in the second quarter, compared to a 1.6% decline in the prior quarter. Equities Trading UP BigBear.ai Holdings, Inc. (
On Thursday, 930 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was Microsoft (NASDAQ:MSFT). The smallest company by market cap to set a new 52-week low was FedNat Holding (NASDAQ:FNHC). Sunlight Finl Hldgs (NYSE:SUNL) saw the most pronounced move, as shares traded down 54.56% to hit its new 52-week low. Abbott Laboratories (NYSE:ABT)'s stock made the biggest bounce back, actually moving up 0.01% shortly after hitting a new 52-week low. Here are all the stocks that set new 52-week lows on Thursday: Microsoft (NASDAQ:MSFT) shares were down 2.37% for the day, having made a 52-week low